Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

13.51 -2.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.92

Massimo

13.66

Metriche Chiave

By Trading Economics

Entrata

-8.9M

-8M

Vendite

3.7M

139M

P/E

Media del settore

140.9

56.597

Margine di Profitto

-5.724

Dipendenti

1,790

EBITDA

18M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+16.5% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

537M

2.4B

Apertura precedente

15.82

Chiusura precedente

13.51

Notizie sul Sentiment di mercato

By Acuity

50%

50%

135 / 339 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 set 2026, 23:56 UTC

News

Korn Ferry's Board declared a quarterly cash dividend of $0.55 per share, payable October 15. Shares traded roughly flat in after-market hours.

8 set 2026, 23:56 UTC

Social Media
News

Chevron Corp shares are higher in after-market hours following a report on declining OECD strategic petroleum reserves, which may impact oil prices and benefit the company.

8 set 2026, 23:46 UTC

News
Social Media

Warner Bros Discovery Inc. shares are higher in after-market hours following Paramount Skydance's court filings on merger progress, indicating potential $1.88 billion impact.

8 set 2026, 23:41 UTC

News

BJ's Restaurants shares are trading lower in after-market hours following a presentation at the Barclays Consumer Staples Conference focused on a strategic reset.

8 set 2026, 23:41 UTC

News

Boston Beer Company appointed Allison Stransky as Chief Marketing Officer, effective October 12, 2026. Shares are trading higher in after-market hours.

8 set 2026, 23:41 UTC

News

Goldman Sachs has agreed to acquire NEOS Investments for $2.25 billion, with shares trading lower in after-market hours following the announcement.

8 set 2026, 23:36 UTC

News
Correlated Moves

Piper Sandler initiated coverage of Quanta Services with an Overweight rating. Shares rose in after-market trading, closing at $624.41.

8 set 2026, 23:36 UTC

News

Shutterstock Inc appointed three new board members to enhance governance. Shares are trading higher after the announcement of Timothy Adams, Matthew Salzberg, and Michael Thompson.

8 set 2026, 23:36 UTC

News

Air Products and Chemicals reported stronger third-quarter profitability, boosting full-year guidance. Shares traded higher in after-market hours following the results.

8 set 2026, 23:31 UTC

News

NetApp shares are trading higher in after-market hours following CEO George Kurian's discussion at the Goldman Sachs Communacopia + Technology Conference.

8 set 2026, 23:31 UTC

News

Estee Lauder Companies announced expanded leadership roles for Brian Franz and Amber English. Shares traded lower during after-market hours following the news.

8 set 2026, 23:21 UTC

News

Prestige Consumer Healthcare Inc shares are lower in after-market trading amid geopolitical tensions and inflation concerns affecting market sentiment across sectors.

8 set 2026, 23:21 UTC

News

Target Corp shares are higher in after-market trading, supported by recent turnaround efforts despite an analyst downgrade to a hold rating.

8 set 2026, 23:21 UTC

News

Tapestry Inc gains in after-market trading, with a market cap of $23.69 billion. A $100 investment five years ago is now worth approximately $290.54.

8 set 2026, 23:16 UTC

News

Stanley Black & Decker shares are higher in after-market trading following the announcement of CEO Chris Nelson's upcoming presentation at a Morgan Stanley conference.

8 set 2026, 23:11 UTC

News

Travel + Leisure Co shares are higher in after-market hours following the announcement of CFO Erik Hoag's participation in a Goldman Sachs conference on September 14, 2026.

8 set 2026, 23:06 UTC

News

Lowe's CEO Marvin R. Ellison will participate in a Goldman Sachs conference on September 15, 2026. Shares are higher in after-market trading.

8 set 2026, 23:06 UTC

Social Media
News
Correlated Moves

Citigroup plans to offer instant cross-border payments using blockchain technology for Japanese firms. Shares are higher in after-market trading following the announcement.

8 set 2026, 23:06 UTC

Social Media
News

General Electric shares rise in after-market hours amid interest in strategic developments, including a $11.75 billion acquisition and potential valuation boost for Precision Castparts.

8 set 2026, 23:06 UTC

News

Eli Lilly's Mounjaro received FDA approval to reduce heart-attack and stroke risk in adults with type 2 diabetes. Shares advanced slightly in after-market trading.

8 set 2026, 23:06 UTC

News

NextEra Energy Inc. shares are trading higher in after-market hours as management announces investor meetings to discuss growth expectations and the Dominion Energy merger.

8 set 2026, 23:06 UTC

News

Merck & Co. shares are higher after Karim Mikhail's appointment to lead the FDA's Center for Biologics Evaluation and Research, boosting the company's regulatory reputation.

8 set 2026, 23:06 UTC

News

General Mills has filed an antitrust lawsuit against major U.S. sugar producers for alleged price collusion, with shares trading higher in after-market hours.

8 set 2026, 23:06 UTC

News

VICI Properties Inc. shares are trading higher in after-market hours following the release of its 2025-2026 Corporate Responsibility Report, highlighting sustainability efforts.

8 set 2026, 23:06 UTC

Event
News

Roivant Sciences Ltd shares are lower in after-market hours despite positive Phase 2 trial results for mosliciguat targeting pulmonary hypertension.

8 set 2026, 23:01 UTC

Social Media
News

AT&T's CEO highlights growth potential and $45B shareholder return plan at Goldman Sachs conference; shares rise in after-market hours.

8 set 2026, 23:01 UTC

News

Ares Capital Corp priced a $750 million public offering of unsecured notes, aiming to enhance financial flexibility. Shares are trading higher in after-market hours.

8 set 2026, 23:01 UTC

News

Constellation Brands plans to redeem $600 million in Senior Notes due 2027, contributing to a rise in shares during after-market trading.

8 set 2026, 23:01 UTC

Correlated Moves
News
Event
Social Media

Braze Inc shares fell sharply in after-hours trading despite strong second-quarter results, as weaker third-quarter EPS guidance raised investor concerns.

8 set 2026, 23:01 UTC

Social Media
News

GameStop shares fell in after-hours trading despite reporting adjusted EPS of $0.27 and raising its fiscal year 2026 EBITDA outlook to over $650 million.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

16.5% in crescita

Previsioni per 12 mesi

Media 16.17 USD  16.5%

Alto 18.5 USD

Basso 14 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

135 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat